Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy.

Ciuleanu, Tudor-Eliade; Samarzjia, M.; Demidchik, Yuri E.; Beliakouski, V.; Rančić, Milan; Bentsion, Dimitri L.; Орлов, С. В.; Schaeffler, Barbara; Jager, Robert L. De; Breitz, Hazel B.

doi:10.1200/jco.2010.28.15_suppl.7002

Cited by 33 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study did not find any difference in OS between the arms (21 weeks vs 20 weeks, p = 0.09). A retrospective subgroup analysis of refractory patients or patients relapsed within 45 days showed that patients in the picoplatin arm achieved longer OS (21.2 weeks vs 18.4 weeks, p = 0.0173) which however does not seem to be clinically meaningful [24].…”

Section: Discussionmentioning

confidence: 78%

Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: A multi-institutional retrospective analysis

et al. 2011

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 78%

Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: A multi-institutional retrospective analysis

et al. 2011

View full text Add to dashboard Cite

“…Picoplatin is a new platinum compound designed to overcome platinum resistance and has shown less neurotoxicity and nephrotoxicity than other platinum agents. But a randomized control study with picoplatin versus best supportive care in chemo sensitive and refractory patients, failed to show any improvement in overall survival 61,62…”

Section: Experimental Treatmentsmentioning

confidence: 99%

Current and Emerging Pharmacotherapies for the Treatment of Relapsed Small Cell Lung Cancer

Nair

Bhanderi

Jafri

2011

Clin Med Insights Oncol

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) is a very aggressive cancer with poor outcome if left untreated, but it is also one of the most chemotherapy responsive cancers. Overall it has a very poor prognosis especially if it is chemotherapy resistant to first line treatment. Second line chemotherapy has not been very beneficial in SCLC as opposed to breast cancer and lymphoma. In the last few years topotecan is the only drug that has been approved by the food and drug administration (FDA) for the second line treatment of SCLC but in Japan another drug, amrubicin is approved. There are many combinations of different chemotherapies available in moderate to high intensity, in this difficult to treat patient to overcome the chemo resistance, but many of these studies are small or phase II trials. In this article we have reviewed single agent and multidrug regimens that were studied in both chemo sensitive and refractory setting, including the most recent clinical trials.

show abstract

“…It proved to be eff ective in relapsed SCLC showing no relevant cardiotoxicity in phase II trials and led to approval in Japan although results of phase III trials are still pending [4]. In contrast to amrubicin, no signifi cant activity could be seen in a phase III trial with picoplatin compared with BSC, referring to a presentation at this years' ASCO meeting [26].…”

Section: Chemotherapy In Ed-sclcmentioning

confidence: 96%

SCLC – The forgotten entity

Ploner

2011

memo

View full text Add to dashboard Cite

As interest in biomarkers, staging and treatment of NSCLC has dramatically increased in the past years, the opposite is true for SCLC. Th e number of abstracts dealing with SCLC presented during the past ASCO meetings amounts to only oneeighth of the number of abstracts on NSCLC. Some specifi c reasons may be responsible for the decrease in applied research in SCLC. Th e incidence of SCLC has dropped over the last decades mainly due to changes in smoking habits, whereas eff orts to improve survival by means of systemic treatment have been stagnating for years. One of the rare appreciable improvements impacting survival of patients with ES-SCLC was made with prophylactic cranial irradiation (PCI) treatment. On the basis of recently published data, it seems that revisiting past experience with surgery in LS-SCLC may be one of the most promising perspectives to regain interest in tailored therapy in SCLC. In many malignancies targeted therapies have been successfully applied in the meantime. Developments in targeted therapy aiming at SCLC are lagging far behind, for example NSCLC. None of the abstracts concerning SCLC presented at this year's ASCO showed an improvement in survival and even worse is that only one phase III trial was presented in the lung cancer session and this trial showed negative results.

show abstract

Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy.

Cited by 33 publications

References 0 publications

Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: A multi-institutional retrospective analysis

Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: A multi-institutional retrospective analysis

Current and Emerging Pharmacotherapies for the Treatment of Relapsed Small Cell Lung Cancer

SCLC – The forgotten entity

Contact Info

Product

Resources

About